Skip Ribbon Commands
Skip to main content


Sirolimus Eluting Coronary Stent System


Understanding complexity, for optimal vessel recovery

Pushing the boundaries of science and medical engineering for the improvement of health: Ultimaster combines an optimal balance between stent design for ultimate conformability with simultaneous polymer resorption and drug release, to match the procedure-triggered biological response in the vessel.1 This results in optimal vessel recovery and potentially shortened DAPT time.2

Mastering rapid and healthy coronary vascular repair.


  • Drug dose and delivery facilitate early vessel recovery

    • ​Terumo's second-generation bioresorbable polymer coating (PDLLA /PCL) eliminates the long-term polymer exposure1
    •  Targeted abluminal drug delivery allows a reduced drug dose4
      • Half the amount required versus circumferential coating to deliver the same amount of drug to target tissue
      • Luminal side of the stent free from drug and polymer enhances endothelial coverage4

  • Gradient coating reduces risk of polymer cracking and delamination3

    ​​No drug polymer coating on parts of the stent that experience the most physical stress.5

  • Ultimaster provides the optimal balance between stent strut coverage, radial force, and visibility

    • ​Thick enough to:
      • Make the stent easy to see, for ease of deployment
      • Maintain radial force across the stent
    •  Thin enough to:
      • Maintain flexibility of the stent
      • Ensure stent coverage

  • The more complex the task, the more relevant the stent performance

    • Famous Terumo hydrophilic coating on delivery system, stent flexibility and smooth stent-balloon transition enable ultimate stent crossability
    • Low entry profile eliminates the gap between the tip and the guidewire for outstanding trackability

  • Designed towards facilitating the treatment of the most challenging bifurcations6

    • ​Open cell, 2-link design for easy side-branch access

    • Uniform architecture for optimal coverage of bifurcation anatomy

    • Gradient coating ensures polymer integrity reducing risk of delamination, even when overexpanded3

    • Side branch expansion

    • Test method: Expand a cell with a balloon at nominal pressure

    • Cell area: 14.5 mm²


Video instructions




Clinical evidence

TCD-10023PK Trial

20 patients, single arm, pharmocokinetics. Published.

TCD-10023PK Trial

20 patients, single arm, pharmocokinetics. Published.


​60 MVD patients with OFDI, single arm, primary endpoint TLF @ 12M. Published

See all clinical evidence

General specifications

​Stent Specifications

Stent designOpen cell
Stent materialCobalt Chromium L605
Strut thickness80 μm
​Cell size (for 3 mm stent)

​4.57 mm²

Drug dose3.9 μg/mm stent length
PolymerPoly (DL-lactide-co-caprolactone)
CoatingAbluminal & gradient
Polymer degradation time and drug release3-4 months

Item specifications

Length (mm) ​Diameter (mm) ​ ​ ​ ​ ​


Recommended DES in ESC/EACTS 2014 guidelines.6

1 month DAPT. CE Mark approved for patients in need.2


1 Data on file at Terumo Corporation (Doc nr. BioRes02-T).
2 Ultimaster IFU. 1 month DAPT CE Mark approved for patients in need. Patients should be maintained on clinically adequate post-procedural antiplatelet therapy according to the current guidelines. In case of need, dual antiplatelet therapy can be discontinued earlier, but not before one month.
3 ​Comparing to DES with uniform coating. Saito N. et al. Drug diffusion and biological responses of arteries using a drug-eluting stent with nonuniform coating. Medical Devices: Evidence and Research 2016:9.
4 Virmani R. CvPath Rabbit Iliac artery. Barbato E. Presented at EuroPCR 2013.
5 Data on file at Terumo Corporation (Doc nr. Grad01-T).
6 Orvin K et al. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial. Catheter Cardiovasc Inter v. 2015 Aug 13. doi: 10.1002/ccd.26150.
7 ​Windecker S et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619.

Do you need more info about this product?

Our sales representatives are here for you.

Contact us
Send us a message
I have read and accept Terumo Privacy And Cookies Policy and the Terms Of Use*
I wish to receive information and marketing updates from Terumo.
* mandatory fields

Thank you for contacting us!

We typically respond within 2 business days and will come back to you as soon as possible.

Didn't find your product?

Consult our products in our Product Index

Are you a healthcare professional?

This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public

For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.